drugset

drugset / Trial / NCT05099848

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

NCT05099848 ↗

Phase 2 Completed 21 enrolled Shandong Cancer Hospital and Institute Jiangsu HengRui Medicine Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma.

Timeline

Start: 2021-03-17
Primary completion: 2024-01-31
Completion: 2024-05-31

Publications

Yalikun K, Li Z, Zhang J, Chang Z, Li M, Sun Z, Liu Z, Yang Y, Xu L, Li L, Zhang C, Sun P, Zhong J, Cui K, Shi X, Zhang B, Zhao L. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. BMC Cancer. 2025 May 7;25(1):838. doi: 10.1186/s12885-025-14250-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Leucovorin	Small molecule	400 mg/m2	Other
Subject	Oxaliplatin	Small molecule	85 mg/m2	Other
Subject	Rivoceranib	Small molecule	250 mg	Oral
Subject	fluorouracil	Small molecule	2500 mg/m2	Other

Indications